Review





Similar Products

primary antibodies for serca2a 2a7-a1  (Thermo Fisher)
90
Thermo Fisher primary antibodies for serca2a 2a7-a1
Primary Antibodies For Serca2a 2a7 A1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pm37296659-103-8-20?v=Thermo+Fisher
Average 90 stars, based on 1 article reviews
primary antibodies for serca2a 2a7-a1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
serca2a primary antibody cst4388  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc serca2a primary antibody cst4388
Protein expression levels and representative images. ( a ) <t>SERCA2a</t> protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
Serca2a Primary Antibody Cst4388, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pmc11476658-305-22-38?v=Cell+Signaling+Technology+Inc
Average 90 stars, based on 1 article reviews
serca2a primary antibody cst4388 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
serca2a primary antibodies  (ABclonal Biotechnology)
90
ABclonal Biotechnology serca2a primary antibodies
Protein expression levels and representative images. ( a ) <t>SERCA2a</t> protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
Serca2a Primary Antibodies, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pm39260321-77-6-11?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews
serca2a primary antibodies - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
primary antibodies for serca2a  (ABclonal Biotechnology)
90
ABclonal Biotechnology primary antibodies for serca2a
Protein expression levels and representative images. ( a ) <t>SERCA2a</t> protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
Primary Antibodies For Serca2a, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pm38761356-305-6-9?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews
primary antibodies for serca2a - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
primary antibodies anti-serca2a  (Badrilla Inc)
90
Badrilla Inc primary antibodies anti-serca2a
Protein expression levels and representative images. ( a ) <t>SERCA2a</t> protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.
Primary Antibodies Anti Serca2a, supplied by Badrilla Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pmc11221812-63-1-10?v=Badrilla+Inc
Average 90 stars, based on 1 article reviews
primary antibodies anti-serca2a - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
serca2a  (Bio-Rad)
96
Bio-Rad serca2a
Figure 2. Exogenous cBIN1 normalizes membrane microdomains at t-tubules. (A) Representative transmission electron microscopy images of post- treatment hearts (scale bar: 1 μm) from each group (left). Quantification of the degree of contour of t-tubules (n = 100–101 t-tubules from 16–40 images of 2–3 myocardial sections and 3 hearts from each group). Data are presented as percentage of t-tubules. χ2 test was used to compare t-tubule contour between groups. *** indicates P < 0.001 for db/m + GFP versus db/db + GFP; ††† indicates P < 0.001 for db/db + GFP versus db/db + cBIN1. (B) Western blots of cBIN1, <t>SERCA2a,</t> CaV1.2, RyR2, GLUT4, and IRAP in total cardiac microsome and sucrose-gradient isolated TT/jSR fraction (F4) from each group (n = 5 hearts per group). (C) Representative spinning disc confocal images of posttreatment mouse myocardium with power spectrum analysis of boxed areas, and quantification of SERCA2a peak power density at t-tubules (n = 35–44 cells from 3 hearts per group). Nonparametric Kruskal-Wallis test fol- lowed by Dunn’s test was used for comparison between selected pairs. *, **, *** indicates P < 0.05, 0.01, and 0.001, respectively, for comparison versus db/m + GFP; †, ††, ††† indicates P < 0.05, 0.01, 0.001, respectively, for comparison between db/db + GFP and db/db + cBIN1.
Serca2a, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pm37639557-298-24-29?v=Bio-Rad
Average 96 stars, based on 1 article reviews
serca2a - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
primary antibody against serca2a  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc primary antibody against serca2a
Figure 2. Exogenous cBIN1 normalizes membrane microdomains at t-tubules. (A) Representative transmission electron microscopy images of post- treatment hearts (scale bar: 1 μm) from each group (left). Quantification of the degree of contour of t-tubules (n = 100–101 t-tubules from 16–40 images of 2–3 myocardial sections and 3 hearts from each group). Data are presented as percentage of t-tubules. χ2 test was used to compare t-tubule contour between groups. *** indicates P < 0.001 for db/m + GFP versus db/db + GFP; ††† indicates P < 0.001 for db/db + GFP versus db/db + cBIN1. (B) Western blots of cBIN1, <t>SERCA2a,</t> CaV1.2, RyR2, GLUT4, and IRAP in total cardiac microsome and sucrose-gradient isolated TT/jSR fraction (F4) from each group (n = 5 hearts per group). (C) Representative spinning disc confocal images of posttreatment mouse myocardium with power spectrum analysis of boxed areas, and quantification of SERCA2a peak power density at t-tubules (n = 35–44 cells from 3 hearts per group). Nonparametric Kruskal-Wallis test fol- lowed by Dunn’s test was used for comparison between selected pairs. *, **, *** indicates P < 0.05, 0.01, and 0.001, respectively, for comparison versus db/m + GFP; †, ††, ††† indicates P < 0.05, 0.01, 0.001, respectively, for comparison between db/db + GFP and db/db + cBIN1.
Primary Antibody Against Serca2a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pmc10202692__mmc2-519-6-49?v=Cell+Signaling+Technology+Inc
Average 90 stars, based on 1 article reviews
primary antibody against serca2a - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
serca2a protein primary antibody  (Danaher Inc)
86
Danaher Inc serca2a protein primary antibody
Figure 2. Exogenous cBIN1 normalizes membrane microdomains at t-tubules. (A) Representative transmission electron microscopy images of post- treatment hearts (scale bar: 1 μm) from each group (left). Quantification of the degree of contour of t-tubules (n = 100–101 t-tubules from 16–40 images of 2–3 myocardial sections and 3 hearts from each group). Data are presented as percentage of t-tubules. χ2 test was used to compare t-tubule contour between groups. *** indicates P < 0.001 for db/m + GFP versus db/db + GFP; ††† indicates P < 0.001 for db/db + GFP versus db/db + cBIN1. (B) Western blots of cBIN1, <t>SERCA2a,</t> CaV1.2, RyR2, GLUT4, and IRAP in total cardiac microsome and sucrose-gradient isolated TT/jSR fraction (F4) from each group (n = 5 hearts per group). (C) Representative spinning disc confocal images of posttreatment mouse myocardium with power spectrum analysis of boxed areas, and quantification of SERCA2a peak power density at t-tubules (n = 35–44 cells from 3 hearts per group). Nonparametric Kruskal-Wallis test fol- lowed by Dunn’s test was used for comparison between selected pairs. *, **, *** indicates P < 0.05, 0.01, and 0.001, respectively, for comparison versus db/m + GFP; †, ††, ††† indicates P < 0.05, 0.01, 0.001, respectively, for comparison between db/db + GFP and db/db + cBIN1.
Serca2a Protein Primary Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pm35988281-61-7-30?v=Danaher+Inc
Average 86 stars, based on 1 article reviews
serca2a protein primary antibody - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
primary antibody serca2a a010-23s  (Badrilla Inc)
90
Badrilla Inc primary antibody serca2a a010-23s
The effect of <t>SERCA2a</t> blockade with thapsigargin. Representative example of Ca +2 levels recording (fluorescence of Fluo-5N) after adding thapsigargin to the HL-1 cardiomyocytes.
Primary Antibody Serca2a A010 23s, supplied by Badrilla Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serca2a+primary+antibody/pmc09361329-59-17-20?v=Badrilla+Inc
Average 90 stars, based on 1 article reviews
primary antibody serca2a a010-23s - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Protein expression levels and representative images. ( a ) SERCA2a protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.

Journal: International Journal of Molecular Sciences

Article Title: Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes

doi: 10.3390/ijms251910617

Figure Lengend Snippet: Protein expression levels and representative images. ( a ) SERCA2a protein expression level normalized to GAPDH; ( b ) The ratio of p-PLN to PLN; ( c ) The ratio of PLN to SERCA2a. C, Control ( n = 5); D, Diabetic ( n = 5); SV, Sacubitril/valsartan-treated diabetic ( n = 5); and V, Valsartan-treated diabetic ( n = 4). *, p < 0.05; **, p < 0.01 compared to control.

Article Snippet: GAPDH (14C10) primary antibody (CST2118S) (RRID: AB_561053), PLN primary antibody (CST8495) (RRID: AB_10949105), p-PLN (PLN ser16/thr17 ) primary antibody (CST8496) (RRID: AB_10949102), SERCA2a primary antibody (CST4388) (RRID: AB_2227684), and antirabbit secondary antibody (CST7074) (RRID: AB_2099233) were obtained from Cell Signaling (Danvers, Massachusetts, USA).

Techniques: Expressing, Control

Figure 2. Exogenous cBIN1 normalizes membrane microdomains at t-tubules. (A) Representative transmission electron microscopy images of post- treatment hearts (scale bar: 1 μm) from each group (left). Quantification of the degree of contour of t-tubules (n = 100–101 t-tubules from 16–40 images of 2–3 myocardial sections and 3 hearts from each group). Data are presented as percentage of t-tubules. χ2 test was used to compare t-tubule contour between groups. *** indicates P < 0.001 for db/m + GFP versus db/db + GFP; ††† indicates P < 0.001 for db/db + GFP versus db/db + cBIN1. (B) Western blots of cBIN1, SERCA2a, CaV1.2, RyR2, GLUT4, and IRAP in total cardiac microsome and sucrose-gradient isolated TT/jSR fraction (F4) from each group (n = 5 hearts per group). (C) Representative spinning disc confocal images of posttreatment mouse myocardium with power spectrum analysis of boxed areas, and quantification of SERCA2a peak power density at t-tubules (n = 35–44 cells from 3 hearts per group). Nonparametric Kruskal-Wallis test fol- lowed by Dunn’s test was used for comparison between selected pairs. *, **, *** indicates P < 0.05, 0.01, and 0.001, respectively, for comparison versus db/m + GFP; †, ††, ††† indicates P < 0.05, 0.01, 0.001, respectively, for comparison between db/db + GFP and db/db + cBIN1.

Journal: JCI insight

Article Title: Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose.

doi: 10.1172/jci.insight.166713

Figure Lengend Snippet: Figure 2. Exogenous cBIN1 normalizes membrane microdomains at t-tubules. (A) Representative transmission electron microscopy images of post- treatment hearts (scale bar: 1 μm) from each group (left). Quantification of the degree of contour of t-tubules (n = 100–101 t-tubules from 16–40 images of 2–3 myocardial sections and 3 hearts from each group). Data are presented as percentage of t-tubules. χ2 test was used to compare t-tubule contour between groups. *** indicates P < 0.001 for db/m + GFP versus db/db + GFP; ††† indicates P < 0.001 for db/db + GFP versus db/db + cBIN1. (B) Western blots of cBIN1, SERCA2a, CaV1.2, RyR2, GLUT4, and IRAP in total cardiac microsome and sucrose-gradient isolated TT/jSR fraction (F4) from each group (n = 5 hearts per group). (C) Representative spinning disc confocal images of posttreatment mouse myocardium with power spectrum analysis of boxed areas, and quantification of SERCA2a peak power density at t-tubules (n = 35–44 cells from 3 hearts per group). Nonparametric Kruskal-Wallis test fol- lowed by Dunn’s test was used for comparison between selected pairs. *, **, *** indicates P < 0.05, 0.01, and 0.001, respectively, for comparison versus db/m + GFP; †, ††, ††† indicates P < 0.05, 0.01, 0.001, respectively, for comparison between db/db + GFP and db/db + cBIN1.

Article Snippet: For V5, SERCA2a, GLUT4, and IRAP labeling, permeabilized and blocked tissue sections or fixed cardiomyocytes were incubated with primary antibodies against V5 (V8317-2MC, Sigma-Aldrich), SERCA2a (ab2861, Abcam), GLUT4 (4670-1725GA, Bio-Rad Laboratories), or IRAP (6918S, Cell Signaling Technology) overnight at 4°C.

Techniques: Membrane, Transmission Assay, Electron Microscopy, Western Blot, Isolation, Comparison

Figure 5. AAV9-cBIN1 normalizes cardiac proteomics in diabetic mice. (A) Bar graphs of LFQ LC-MS/MS data (fold changes over control db/m mice) of SERCA2a, RyR2, GLUT4, and IRAP from the db/m mice treated with AAV9-GFP (n = 4 hearts) and db/db mice treated with AAV9-GFP (n = 4 hearts) or cBIN1 (n = 3 hearts). (B) PCA plot of all 3 groups (n = 2 repeats/heart × 3–4 hearts/group) generated based on LFQ LC-MS/MS proteomics. All data are presented as mean ± SEM. One-way ANOVA followed by Bonferroni’s test or Kruskal-Wallis test followed by Dunn’s test was used for comparison between the selected pairs. * indicates P < 0.05 for comparison versus db/m + GFP; † indicates P < 0.05 for comparison between db/db + GFP and db/db + cBIN1.

Journal: JCI insight

Article Title: Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose.

doi: 10.1172/jci.insight.166713

Figure Lengend Snippet: Figure 5. AAV9-cBIN1 normalizes cardiac proteomics in diabetic mice. (A) Bar graphs of LFQ LC-MS/MS data (fold changes over control db/m mice) of SERCA2a, RyR2, GLUT4, and IRAP from the db/m mice treated with AAV9-GFP (n = 4 hearts) and db/db mice treated with AAV9-GFP (n = 4 hearts) or cBIN1 (n = 3 hearts). (B) PCA plot of all 3 groups (n = 2 repeats/heart × 3–4 hearts/group) generated based on LFQ LC-MS/MS proteomics. All data are presented as mean ± SEM. One-way ANOVA followed by Bonferroni’s test or Kruskal-Wallis test followed by Dunn’s test was used for comparison between the selected pairs. * indicates P < 0.05 for comparison versus db/m + GFP; † indicates P < 0.05 for comparison between db/db + GFP and db/db + cBIN1.

Article Snippet: For V5, SERCA2a, GLUT4, and IRAP labeling, permeabilized and blocked tissue sections or fixed cardiomyocytes were incubated with primary antibodies against V5 (V8317-2MC, Sigma-Aldrich), SERCA2a (ab2861, Abcam), GLUT4 (4670-1725GA, Bio-Rad Laboratories), or IRAP (6918S, Cell Signaling Technology) overnight at 4°C.

Techniques: Liquid Chromatography with Mass Spectroscopy, Control, Generated, Comparison

The effect of SERCA2a blockade with thapsigargin. Representative example of Ca +2 levels recording (fluorescence of Fluo-5N) after adding thapsigargin to the HL-1 cardiomyocytes.

Journal: Anatolian Journal of Cardiology

Article Title: Hypoxia-Induced Sarcoplasmic Reticulum Ca 2+ Leak Is Reversed by Ryanodine Receptor Stabilizer JTV-519 in HL-1 Cardiomyocytes

doi: 10.5152/AnatolJCardiol.2022.1223

Figure Lengend Snippet: The effect of SERCA2a blockade with thapsigargin. Representative example of Ca +2 levels recording (fluorescence of Fluo-5N) after adding thapsigargin to the HL-1 cardiomyocytes.

Article Snippet: After blocking, the membranes were washed using Tris-buffered saline with Tween (TBS-T) and then incubated with primary antibody SERCA2a (A010-23S, Badrilla, Leeds, UK, dilution 1:1000), RyR2 (ARR-002, Alomone Labs, Jerusalem, Israel, dilution 1:1000) and β-tubulin (ab6046, Abcam, Cambridge, UK, dilution 1:1000) overnight.

Techniques: Fluorescence

The effect of hypoxia and Rycal treatment on RyR2 and SERCA2a gene expression. The effect of 7-day hypoxic and normoxic exposure with Rycals/Vehicle (DMSO) treatment on RyR2 and SERCA2a gene expression. n = 6, * P < .050 for comparison with 1% O 2 , # P < .050 for comparison with Vehicle, $ P < .050 for comparison with 0.3 mM (all 1-way ANOVA with Tukey post hoc test).

Journal: Anatolian Journal of Cardiology

Article Title: Hypoxia-Induced Sarcoplasmic Reticulum Ca 2+ Leak Is Reversed by Ryanodine Receptor Stabilizer JTV-519 in HL-1 Cardiomyocytes

doi: 10.5152/AnatolJCardiol.2022.1223

Figure Lengend Snippet: The effect of hypoxia and Rycal treatment on RyR2 and SERCA2a gene expression. The effect of 7-day hypoxic and normoxic exposure with Rycals/Vehicle (DMSO) treatment on RyR2 and SERCA2a gene expression. n = 6, * P < .050 for comparison with 1% O 2 , # P < .050 for comparison with Vehicle, $ P < .050 for comparison with 0.3 mM (all 1-way ANOVA with Tukey post hoc test).

Article Snippet: After blocking, the membranes were washed using Tris-buffered saline with Tween (TBS-T) and then incubated with primary antibody SERCA2a (A010-23S, Badrilla, Leeds, UK, dilution 1:1000), RyR2 (ARR-002, Alomone Labs, Jerusalem, Israel, dilution 1:1000) and β-tubulin (ab6046, Abcam, Cambridge, UK, dilution 1:1000) overnight.

Techniques: Gene Expression, Comparison

The effect of hypoxia and Rycal treatment on RyR2 and SERCA2a protein expression. The effect of 7-day hypoxic and normoxic exposure with Rycals/Vehicle (DMSO) treatment on RyR2 and SERCA2a protein expression. n = 6. No statistically significant comparison.

Journal: Anatolian Journal of Cardiology

Article Title: Hypoxia-Induced Sarcoplasmic Reticulum Ca 2+ Leak Is Reversed by Ryanodine Receptor Stabilizer JTV-519 in HL-1 Cardiomyocytes

doi: 10.5152/AnatolJCardiol.2022.1223

Figure Lengend Snippet: The effect of hypoxia and Rycal treatment on RyR2 and SERCA2a protein expression. The effect of 7-day hypoxic and normoxic exposure with Rycals/Vehicle (DMSO) treatment on RyR2 and SERCA2a protein expression. n = 6. No statistically significant comparison.

Article Snippet: After blocking, the membranes were washed using Tris-buffered saline with Tween (TBS-T) and then incubated with primary antibody SERCA2a (A010-23S, Badrilla, Leeds, UK, dilution 1:1000), RyR2 (ARR-002, Alomone Labs, Jerusalem, Israel, dilution 1:1000) and β-tubulin (ab6046, Abcam, Cambridge, UK, dilution 1:1000) overnight.

Techniques: Expressing, Comparison